Featuring an interview with Dr Raajit K Rampal, including the following topics:

Clinical decision-making in the initiation and stopping of systemic therapy for myelofibrosis (MF) (0:00)
Novel research strategies involving CDK4/6 inhibitors for MF (8:03)
Implications of the JUMP study for clinical practice (10:00)
Therapeutic switching strategies with JAK inhibitors for MF (12:17)
Clinical rationale for the use of luspatercept and elritercept for MF (15:35)
Emerging clinical data involving BET inhibitors for MF (16:57)
Tolerability concerns with selinexor in patients with MF (20:01)
Mechanism of and clinical data with the MDM2 inhibitor navtemadlin for MF (22:32)
Additional novel strategies under clinical investigation for MF (25:52)
Potential transformation of myeloproliferative neoplasms to acute myeloid leukemia (29:40)
Management of polycythemia vera and essential thrombocythemia (34:27)
General management principles for myeloproliferative neoplasms (37:53)

Donald Trump - Die Popkultur arbeitet sich am US-Präsidenten ab